Navigation Links
Cerecor Raises $22 Million Series A Financing
Date:4/4/2012

BALTIMORE, April 4, 2012 /PRNewswire/ -- Cerecor Inc., a biopharmaceutical company focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary activity is in the human nervous system, announced today that it has raised over US$22 million in an overallotment of its January 2012 Series A preferred stock financing. The offering, which was placed with accredited investors including members of Cerecor's Board of Directors, significantly exceeded the offering maximum of US$15 million.  Maxim Group, LLC of New York, NY acted as placement agent in connection with the offering.

(Logo: http://photos.prnewswire.com/prnh/20120404/PH82224LOGO )

"The completion of this financing is an important step in bringing our lead product, FP01 for the treatment of chronic and acute cough, to the market and to support our early preclinical efforts in cognition and schizophrenia. We are delighted by the enthusiastic response to our offering, as it confirms the quality of our Company, its product pipeline and our founding team," stated Blake M. Paterson, M.D., Co-founder & CEO of Cerecor.

About Cerecor Inc.

Cerecor Inc. ("Cerecor" or the "Company") is a biopharmaceutical company focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary activity is in the human nervous system. Cerecor is focused on translational medicine -- the accelerated transfer of technology from the academic laboratory to early human trials, with the goal of rapid commercialization. www.cerecor.com  

For More Information, contact:
John Dierkes
Kennedy Advisors
john@kennedyadvice.com 
(410) 935-9334


'/>"/>
SOURCE Cerecor Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Biotech Firm Spun Off from Childrens Hospital Raises $7 Million to Advance Magnetic-Based Vascular Treatment
2. Cowen Healthcare Royalty Partners Raises $1 Billion
3. Avaxia Biologics, Inc. Raises $2.2 Million in First Closing of Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
4. DLVR Therapeutics Inc. Raises Additional Capital Adding MaRS Innovation to Investor Base
5. Cleave Biosciences Raises $42 Million in Series A Financing for Novel Cancer Therapies
6. Dyadic International Raises $3 Million in Private Placement of Convertible Notes
7. Creabilis Raises €15M ($20M) in Series B Fundraising Round
8. SironRX Therapeutics Raises $3.4 Million Series A
9. PPTA Praises Legislation That Protects the Treatment of Rare Diseases
10. Evergreen Foundation Gala Raises $1.16 Million for Cancer Care, Kicks off Capital Campaign
11. FireFly® Toothbrush Facebook Campaign Raises Funds for Smile Train
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2017)... ... August 23, 2017 , ... NDA Partners Chairman Carl Peck, ... Office of Device Evaluation at the FDA’s Center for Devices and Radiological Health and ... as an Expert Consultant. , Prior to his FDA experience, Dr. Sheets served in ...
(Date:8/22/2017)... ... 2017 , ... One of the biggest opportunities to reduce ... Opioid-dose sparing refers to the reduction of opioid dosage by combining with a ... , The potential for new therapies to replace opioids and/or reduce dosages, however, ...
(Date:8/21/2017)... ... August 21, 2017 , ... MacArthur ... of Hawaii, is pleased to announce the first Delos Wellness Signature™ residence in ... International Realty is working together with listing agent Kelly Allen, R(S) of Carvill ...
(Date:8/21/2017)... ... 21, 2017 , ... Boston Strategic Partners, Inc. (BSP), a ... and Outcomes Research (HEOR) and ‘big data’ to provide a variety of in-depth ... $3.0 trillion with nearly 1/3 spent on hospitalizations. BSP has access to real-world ...
Breaking Biology Technology:
(Date:6/14/2017)... PARIS , June 15, 2017  IBM (NYSE: IBM ... the international tech event dedicated to developing collaboration between startups ... on June 15-17. During the event, nine startups will ... deliver value in various industries. ... in the international market, with a 30 percent increase in ...
(Date:4/24/2017)... 2017 Janice Kephart , former ... Strategy Partners, LLP (IdSP) , today issues the ... Trump,s March 6, 2017 Executive Order: Protecting ... can be instilled with greater confidence, enabling the ... refugee applications are suspended by until at least ...
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market by ... Service, Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast to ... USD 14.30 Billion in 2017 to USD 31.75 Billion by 2022, at ... ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):